On Monday, CME Group Cl A received a positive adjustment to its Relative Strength (RS) Rating, from 80 to 83.
IBD's unique rating tracks market leadership with a 1 (worst) to 99 (best) score. The rating shows how a stock's price performance over the trailing 52 weeks stacks up against all the other stocks in our database.
Over 100 years of market history reveals that the stocks that go on to make the biggest gains tend to have an RS Rating of over 80 as they launch their biggest runs.
Looking For The Best Stocks To Buy And Watch? Start Here
CME Group Cl A is trading within a buy zone after moving past a 249.02 buy point in a cup without handle. The proper buying range is up to 5% above the initial entry. Once a stock hits that benchmark, it's best to hold off investing and wait for it to set up another buying opportunity.
CME Group Cl A reported 6% earnings growth in the latest quarterly report. Sales rose 6%.
CME Group Cl A earns the No. 10 rank among its peers in the Financial Services-Specialty industry group. Marex Group, Sezzle and X Financial ADR are among the top 5 highly rated stocks within the group.
RELATED:
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
